Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Harnessing innate lung anti-cancer effector functions with a novel bacterial-derived immunotherapy.

Bazett M, Costa AM, Bosiljcic M, Anderson RM, Alexander MP, Wong SWY, Dhanji S, Chen JM, Pankovich J, Lam S, Sutcliffe S, Gunn H, Kalyan S, Mullins DW.

Oncoimmunology. 2017 Nov 27;7(3):e1398875. doi: 10.1080/2162402X.2017.1398875. eCollection 2018.

2.

CXCR3+ monocytes/macrophages are required for establishment of pulmonary metastases.

Butler KL, Clancy-Thompson E, Mullins DW.

Sci Rep. 2017 Mar 30;7:45593. doi: 10.1038/srep45593.

3.

Systematic Pan-Cancer Analysis Reveals Immune Cell Interactions in the Tumor Microenvironment.

Varn FS, Wang Y, Mullins DW, Fiering S, Cheng C.

Cancer Res. 2017 Mar 15;77(6):1271-1282. doi: 10.1158/0008-5472.CAN-16-2490. Epub 2017 Jan 26.

4.

Adaptive immunity programmes in breast cancer.

Varn FS, Mullins DW, Arias-Pulido H, Fiering S, Cheng C.

Immunology. 2017 Jan;150(1):25-34. doi: 10.1111/imm.12664. Epub 2016 Sep 20. Review.

5.

Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases.

Mauldin IS, Wages NA, Stowman AM, Wang E, Olson WC, Deacon DH, Smith KT, Galeassi N, Teague JE, Smolkin ME, Chianese-Bullock KA, Clark RA, Petroni GR, Marincola FM, Mullins DW, Slingluff CL Jr.

Cancer Immunol Immunother. 2016 Oct;65(10):1201-12. doi: 10.1007/s00262-016-1880-z. Epub 2016 Aug 13.

6.

Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases.

Mauldin IS, Wages NA, Stowman AM, Wang E, Smolkin ME, Olson WC, Deacon DH, Smith KT, Galeassi NV, Chianese-Bullock KA, Dengel LT, Marincola FM, Petroni GR, Mullins DW, Slingluff CL Jr.

Cancer Immunol Immunother. 2016 Oct;65(10):1189-99. doi: 10.1007/s00262-016-1881-y. Epub 2016 Aug 13.

7.

The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells.

Whipple CA, Boni A, Fisher JL, Hampton TH, Tsongalis GJ, Mellinger DL, Yan S, Tafe LJ, Brinckerhoff CE, Turk MJ, Mullins DW, Fadul CE, Ernstoff MS.

Melanoma Res. 2016 Jun;26(3):223-35. doi: 10.1097/CMR.0000000000000244.

PMID:
26974965
8.

Integrative analysis of breast cancer reveals prognostic haematopoietic activity and patient-specific immune response profiles.

Varn FS, Andrews EH, Mullins DW, Cheng C.

Nat Commun. 2016 Jan 4;7:10248. doi: 10.1038/ncomms10248.

9.

Site-Specific Immunomodulator: A Novel Treatment for Crohn's Disease.

Bressler B, Bethel KP, Kleef R, Reynolds SL, Sutcliffe S, Mullins DW, Gunn H.

Gastroenterol Res Pract. 2015;2015:231243. doi: 10.1155/2015/231243. Epub 2015 May 12.

10.

Melanoma Induces, and Adenosine Suppresses, CXCR3-Cognate Chemokine Production and T-cell Infiltration of Lungs Bearing Metastatic-like Disease.

Clancy-Thompson E, Perekslis TJ, Croteau W, Alexander MP, Chabanet TB, Turk MJ, Huang YH, Mullins DW.

Cancer Immunol Res. 2015 Aug;3(8):956-67. doi: 10.1158/2326-6066.CIR-15-0015. Epub 2015 Jun 5.

11.

The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.

Jenkins MH, Croteau W, Mullins DW, Brinckerhoff CE.

Matrix Biol. 2015 Oct;48:66-77. doi: 10.1016/j.matbio.2015.05.007. Epub 2015 May 16.

12.

CXCR3 signaling in BRAFWT melanoma increases IL-8 expression and tumorigenicity.

Jenkins MH, Brinckerhoff CE, Mullins DW.

PLoS One. 2015 Mar 23;10(3):e0121140. doi: 10.1371/journal.pone.0121140. eCollection 2015.

13.

BRAF inhibition alleviates immune suppression in murine autochthonous melanoma.

Steinberg SM, Zhang P, Malik BT, Boni A, Shabaneh TB, Byrne KT, Mullins DW, Brinckerhoff CE, Ernstoff MS, Bosenberg MW, Turk MJ.

Cancer Immunol Res. 2014 Nov;2(11):1044-50. doi: 10.1158/2326-6066.CIR-14-0074. Epub 2014 Sep 2.

14.

Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032.

Jenkins MH, Steinberg SM, Alexander MP, Fisher JL, Ernstoff MS, Turk MJ, Mullins DW, Brinckerhoff CE.

Pigment Cell Melanoma Res. 2014 May;27(3):495-501. doi: 10.1111/pcmr.12220. Epub 2014 Mar 6. No abstract available.

15.

Peptide vaccination in Montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T cells.

Clancy-Thompson E, King LK, Nunnley LD, Mullins IM, Slingluff CL Jr, Mullins DW.

Cancer Immunol Res. 2013 Nov;1(5):332-9. doi: 10.1158/2326-6066.CIR-13-0084.

16.

Differential expression and tumor necrosis factor-mediated regulation of TNFRSF11b/osteoprotegerin production by human melanomas.

Oliver JL, Alexander MP, Norrod AG, Mullins IM, Mullins DW.

Pigment Cell Melanoma Res. 2013 Jul;26(4):571-9. doi: 10.1111/pcmr.12091. Epub 2013 Apr 11.

17.

Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge.

Baird JR, Byrne KT, Lizotte PH, Toraya-Brown S, Scarlett UK, Alexander MP, Sheen MR, Fox BA, Bzik DJ, Bosenberg M, Mullins DW, Turk MJ, Fiering S.

J Immunol. 2013 Jan 1;190(1):469-78. doi: 10.4049/jimmunol.1201209. Epub 2012 Dec 7.

18.

Differential mechanisms of tumor progression in clones from a single heterogeneous human melanoma.

Croteau W, Jenkins MH, Ye S, Mullins DW, Brinckerhoff CE.

J Cell Physiol. 2013 Apr;228(4):773-80. doi: 10.1002/jcp.24225.

19.

Extracellular hepatitis C virus core protein activates STAT3 in human monocytes/macrophages/dendritic cells via an IL-6 autocrine pathway.

Tacke RS, Tosello-Trampont A, Nguyen V, Mullins DW, Hahn YS.

J Biol Chem. 2011 Mar 25;286(12):10847-55. doi: 10.1074/jbc.M110.217653. Epub 2011 Jan 31.

20.

The protein tyrosine phosphatase SHP-1 modulates the suppressive activity of regulatory T cells.

Iype T, Sankarshanan M, Mauldin IS, Mullins DW, Lorenz U.

J Immunol. 2010 Nov 15;185(10):6115-27. doi: 10.4049/jimmunol.1000622. Epub 2010 Oct 15.

21.

Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma.

Dengel LT, Norrod AG, Gregory BL, Clancy-Thompson E, Burdick MD, Strieter RM, Slingluff CL Jr, Mullins DW.

J Immunother. 2010 Nov-Dec;33(9):965-74. doi: 10.1097/CJI.0b013e3181fb045d.

22.

Immunity to melanoma antigens: from self-tolerance to immunotherapy.

Slingluff CL Jr, Chianese-Bullock KA, Bullock TN, Grosh WW, Mullins DW, Nichols L, Olson W, Petroni G, Smolkin M, Engelhard VH.

Adv Immunol. 2006;90:243-95. Review.

PMID:
16730266
23.

Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells.

Chang CC, Ogino T, Mullins DW, Oliver JL, Yamshchikov GV, Bandoh N, Slingluff CL Jr, Ferrone S.

J Biol Chem. 2006 Jul 7;281(27):18763-73. Epub 2006 Apr 28.

24.
25.

Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma.

Yamshchikov GV, Mullins DW, Chang CC, Ogino T, Thompson L, Presley J, Galavotti H, Aquila W, Deacon D, Ross W, Patterson JW, Engelhard VH, Ferrone S, Slingluff CL Jr.

J Immunol. 2005 Jun 1;174(11):6863-71.

26.

CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease.

Mullins IM, Slingluff CL, Lee JK, Garbee CF, Shu J, Anderson SG, Mayer ME, Knaus WA, Mullins DW.

Cancer Res. 2004 Nov 1;64(21):7697-701.

28.

Tumor-derived cytokines dysregulate macrophage interferon-gamma responsiveness and interferon regulatory factor-8 expression.

Mullins DW, Martins RS, Elgert KD.

Exp Biol Med (Maywood). 2003 Mar;228(3):270-7.

PMID:
12626771
30.

A male genital tract-specific carbohydrate epitope on human CD52: implications for immunocontraception.

Norton EJ, Diekman AB, Westbrook VA, Mullins DW, Klotz KL, Gilmer LL, Thomas TS, Wright DC, Brisker J, Engelhard VH, Flickinger CJ, Herr JC.

Tissue Antigens. 2002 Nov;60(5):354-64.

PMID:
12492811
31.

Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy.

Engelhard VH, Bullock TN, Colella TA, Sheasley SL, Mullins DW.

Immunol Rev. 2002 Oct;188:136-46. Review.

PMID:
12445287
32.
33.
34.

Tumor cell-derived TGF-beta and IL-10 dysregulate paclitaxel-induced macrophage activation.

Mullins DW, Martins RS, Burger CJ, Elgert KD.

J Leukoc Biol. 2001 Jan;69(1):129-37.

PMID:
11200057
35.

Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use.

Engelhard VH, Bullock TN, Colella TA, Mullins DW.

Cancer J. 2000 May;6 Suppl 3:S272-80. Review.

PMID:
10874498
36.

Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy.

Colella TA, Bullock TN, Russell LB, Mullins DW, Overwijk WW, Luckey CJ, Pierce RA, Restifo NP, Engelhard VH.

J Exp Med. 2000 Apr 3;191(7):1221-32.

37.

Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide.

Mullins DW, Burger CJ, Elgert KD.

J Immunol. 1999 Jun 1;162(11):6811-8.

38.

Tumor growth modulates macrophage nitric oxide production following paclitaxel administration.

Mullins DW, Burger CJ, Elgert KD.

Int J Immunopharmacol. 1998 Oct;20(10):537-51.

PMID:
9839658
39.

Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation.

Mullins DW, Koci MD, Burger CJ, Elgert KD.

Immunopharmacol Immunotoxicol. 1998 Nov;20(4):473-92.

PMID:
9805229
40.

Tumor-induced immune dysfunction: the macrophage connection.

Elgert KD, Alleva DG, Mullins DW.

J Leukoc Biol. 1998 Sep;64(3):275-90. Review.

PMID:
9738653
41.

Taxol-mediated changes in fibrosarcoma-induced immune cell function: modulation of antitumor activities.

Mullins DW, Walker TM, Burger CJ, Elgert KD.

Cancer Immunol Immunother. 1997 Oct;45(1):20-8.

PMID:
9353423
42.
43.

The science literacy crisis, philosophical issues, and the origin sciences.

Mullins DW Jr.

Orig Life Evol Biosph. 1995 Oct;25(5):495-510.

PMID:
11536700
44.

Effect of hyperthermia and doxorubicin on nucleoid sedimentation and poly (ADP-ribose) polymerase activity in L1210 cells.

Daugherty JP, Simpson TA Jr, Mullins DW Jr.

Cancer Chemother Pharmacol. 1988;21(3):229-32.

PMID:
3129205
45.

Restoration of hyperthermia-associated increased protein to DNA ratio of nucleoids.

Simpson TA Jr, LaRussa PG, Mullins DW Jr, Daugherty JP.

Int J Hyperthermia. 1987 Jan-Feb;3(1):49-62.

PMID:
3559298
46.

Aliphatic amino acid side chains associate with the "face" of the adenine ring.

Lacey JC Jr, Mullins DW Jr, Watkins CL.

J Biomol Struct Dyn. 1986 Feb;3(4):783-93.

PMID:
3271049
47.
48.

Genetic coding catalysis.

Lacey JC Jr, Mullins DW Jr.

J Theor Biol. 1985 Aug 21;115(4):595-601. No abstract available.

PMID:
4046611
49.

Rationalization of some genetic anticodonic assignments.

Lacey JC Jr, Hall LM, Mullins DW Jr.

Orig Life Evol Biosph. 1985;16(1):69-79.

PMID:
3867845
50.

Chirally selective, intramolecular interaction observed in an aminoacyl adenylate anhydride.

Lacey JC Jr, Hall LM, Mullins DW Jr, Watkins CL.

Orig Life Evol Biosph. 1985;16(2):151-6.

PMID:
3835505

Supplemental Content

Loading ...
Support Center